Citizens Maintains Market Outperform on Progyny, Raises Price Target to $31

Progyny

Progyny

PGNY

0.00

Citizens analyst Constantine Davides maintains Progyny (NASDAQ: PGNY) with a Market Outperform and raises the price target from $30 to $31.